# To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

> **NCT05867550** · PHASE4 · COMPLETED · sponsor: **Bahria University** · enrollment: 162 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** Rifaximin 550 MG
- **DRUG:** Mebeverine 135 MG
- **DRUG:** Psyllium Husk
- **DRUG:** Amitriptyline Hydrochloride 25 MG

## Key facts

- **NCT ID:** NCT05867550
- **Lead sponsor:** Bahria University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-03
- **Primary completion:** 2023-03-27
- **Final completion:** 2023-06-10
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05867550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05867550, "To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05867550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*